Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Broker tips: HSBC, Hikma, Pearson
(Sharecast News) - Berenberg upgraded HSBC to 'buy' from 'hold' on Wednesday, keeping the price target at 780p, as it said the bank's return on tangible equity of around 13% and attractive growth potential are undervalued. "HSBC's footprint is structurally attractive," Berenberg said. "As well as providing the bank with access to faster-growing markets, HSBC's global presence means it is well placed to provide high-returning transaction banking services for global corporates.
"This structural strength was previously eclipsed by cyclical headwinds and uncertainty related to HSBC's restructuring. More recently, however, higher interest rates have supported HSBC's returns and risks from restructuring are now modest."
Berenberg said that strengthening activity, particularly in Asia, provides further cyclical support, and growth can be supported further by the bank's recent investments.
RBC Capital Markets lifted its price target on Hikma Pharmaceuticals to 2,050p from 1,950p as it reiterated its 'outperform' rating.
The bank noted that price erosion is moderating in the US generics market largely due to improving supply side dynamics.
"As a result Hikma has raised guidance for the Generics division to close to 20% revenue growth from low double digits.
"However, exchange rates in the MENA region have deteriorated further (particularly Egypt) which will negatively impact the branded division.
"We update our model for improved pricing in Generics and latest exchange rates in MENA, resulting in modest forecast changes."
JP Morgan kept its 'overweight' rating on Pearson, arguing that the educational publisher is not as exposed to the potential threat of artificial intelligence as some of its rivals.
Shares in education services specialists fell sharply on Tuesday after US firm Chegg warned about the impact of ChatGPT on its homework help services. It tumbled 48%, while London-listed Pearson shed 10%.
But JP Morgan - which has a target price of 1,230p on Pearson - said in a note: "While ChatGPT could be seen as an alternative for students seeking answers to their homework, we do not see it as an alternative to Pearson's text books, courseware and learning platforms that provide trusted programmes that are adopted by colleges, and have to be followed and consumed by students for around 70% of higher education courses.
"The difference is that Pearson provides the content and sets the questions, whereas Chegg and ChatGPT provide answers to those questions.
"In our view, ChatGPT/AI will not provide complete and structured learning programmes with trusted content."
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.